Stifel analyst Annabell Samimy reiterated a Buy rating and $18.00 price target on Altimmune (NASDAQ: ALT).The analyst commented, “We hosted ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE